Abliva Announces Issuance of a New U.S. Patent for Therapeutic Compound NV354
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the granting of a composition of ...